

First name	Eva
Last name	Wardelmann
Academic title	Univ. Prof. , Dr. med.
Position	Director and Chair Gerhard-Domagk-Institute of Pathology, University Hospital Münster Leader of the German GIST and Sarcoma Registry Münster

RESEARCH FIELD

Dr. Wardelmann is specialized on soft tissue tumors and is leader of the German GIST and Sarcoma Registry (located in Münster). Since more than 30 years, one of her major interests is on Gastrointestinal Stromal Tumors. She serves as reference pathologist for the German Interdisciplinary Sarcoma Group (GISG), for the Soft Tissue and Bone Sarcoma Group of the EORTC (European Organization for Research and Treatment of Cancer) and for the SSG (Scandinavian Sarcoma Group) as well as for several IITs. She is heading the German Interlaboratory Test for CD117 immunohistochemistry (QuiP), and is founder member of the German Sarcoma Foundation (Deutsche Sarkomstiftung – DSS). She is visiting professor at the Yerevan State Medical University in Armenia.

EDUCATION & TRAINING

1983-1990	Medical School (University of Kiel)
1990-1997	Residency (University Hospital Bonn)
2004	Habilitation and venia legendi in Anatomical and Surgical Pathology (Associate Professor)
2012	W2-professorship for sarcoma pathology at the University Hospital of Cologne

POSITIONS & EMPLOYMENT

2005-	Reference pathologist of the STBSG and SSG
2011-2013	Vice Chair of the Institute of Pathology at the University Hospital of Cologne
2013-	Director and Chair of the Gerhard-Domagk-Institute of Pathology
2013-	Chair of the Gerhard-Domagk-Foundation against Cancer
2014-2022	Chair of the Pathology Subcommittee of the STBSG of the EORTC
2017-2019	President of the German Division of the International Academy of Pathology (IAP)
2018-	Visiting Professor at the Yerevan State Medical University, Armenia
2019-2021	Chair of the Educational Committee of the IAP
since 2020	Committee member (Fachkollegiatin) at the Deutsche Forschungsgemeinschaft (DFG)
since 2023	Deputy Chair of the German Society of Pathology (DGP)

CLINICAL TRIAL EXPERIENCE (as reference pathologist for Sarcomas and GIST)

APOLLON:	Neoadjuvant treatment of GIST with Imatinib
CAMN107DDE05:	Nilotinib in metastatic GIST pretreated with Imatinib and Sunitinib, third line
CAMN107DDE06:	Nilotinib in metastatic GIST, first line
PROGRESS:	Nilotinib vs BSC/Imatinib/Sunitinib in GIST
CAMN107DDE12:	Localized gastrointestinal stromal tumors (GIST): single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at least 1 year of adjuvant imatinib mesylate.
RELAX:	CSTI571JDE74 - open access study for adjuvant treatment of localized GIST with Imatinib
CRAD001C2454:	Everolimus in GIST resistant to Imatinib and Sunitinib
EORTC 62024:	Clinical trial comparing 24 months vs observation of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs)
SSGXVIII/AIO:	Clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs)
SSGXII:	Phase III Study: Three vs. five years of adjuvant Imatinib in operable high-risk GIST
ACT.IN.SARC:	Phase II-III Study: Evaluation of the safety and efficacy of the hafnium oxide (HfO ₂) nanoparticle NBTXR3 activated by radiotherapy in advanced sarcomas

ACTIVITIES IN THE SCIENTIFIC COMMUNITY AND OTHER EXPERIENCES

Reviewer: Lancet Oncology, JCO, Journal of Pathology, Gastroenterology, Cancer Research, Clinical Cancer Research, Cancer Genetics, European Journal of Cancer, PNAS, and more
DFG, Deutsche Krebshilfe, Wilhelm-Sander-Stiftung, Else-Kröner-Fresenius-Stiftung, Österreichische Gesellschaft für Hämatologie und Medizinische Onkologie (OeGHO)

Medical and scientific organizations: DGP (German Society of Pathology), IAP (International Academy of Pathology), ESMO (European Society of Medical Oncology), CTOS (Connective Tissue Oncological Society), DKG (German Cancer Society), DSS (German Sarcoma Foundation), STBSG of the EORTC (Soft Tissue and Bone Sarcoma Group)

PUBLICATIONS (peer-reviewed and published or accepted for publication), 5 most important publications from the last 5 years (ideally but not necessarily with context to the project)

ORCID: <https://orcid.org/0000-0001-6788-4910>

h-index: 73 i10-index: 224

1. Mühlenberg T, Falkenhorst J, Schulz T, Fletcher BS, Teuber A, Krzesciesa D, Klooster I, Lundberg M, Wilson L, Lategahn J, von Mehren M, Grunewald S, Tüns AI, **Wardelmann E**, Sicklick JK, Brahmi M, Serrano C, Schildhaus HU, Sievers S, Treckmann J, Heinrich MC, Raut CP, Ou WB, Marino-Enriquez A, George S, Rauh D, Fletcher JA, Bauer S. ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape. **J Clin Oncol** (2024) in press
2. Joensuu H, **Wardelmann E**, Eriksson M, Reichardt A, Hall KS, Schütte J, Cameron S, Hohenberger P, Sihto H, Jost PJ, Lindner LH, Bauer S, Nilsson B, Kallio R, Pesonen T, Reichardt P.: KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial. **Clin Cancer Res.** (2023) Sep 1;29(17):3313-3319.
3. Rothermundt C, Andreou D, Blay JY, Brodowicz T, Desar IME, Dileo P, Gelderblom H, Haas R, Jakob J, Jones RL, Judson I, Kunz WG, Liegl-Atzwanger B, Lindner LH, Messiou C, Miah AB, Reichardt P, Szkandera J, van der Graaf WTA, van Houdt WJ, **Wardelmann E**, Hofer S; Writing committee on behalf of CSSS panellists: Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. **Eur J Cancer** (2023) Feb;180:158-179
4. Grunewald S, Klug LR, Mühlenberg T, Lategahn J, Falkenhorst J, Town A, Ehrh C, **Wardelmann E**, Hartmann W, Schildhaus HU, Treckmann J, Fletcher JA, Jung S, Czodrowski P, Miller S, Schmidt-Kittler O, Rauh D, Heinrich MC, Bauer S*. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. **Cancer Discov.** (2021) Jan;11(1):108-125
5. 10. Ihle MA, Huss S, Jeske W, Hartmann W, Merkelbach-Bruse S, Schildhaus HU, Büttner R, Sihto H, Sundby Hall K, Eriksson M, Reichardt P, Joensuu H, **Wardelmann E**. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. **PLoS One** (2018) Feb 16;13(2):e0193048

THIRD PARTY FUNDING (current and applied for)

Project title (no acronyms)	(potential) Source of funds	Duration (exact start and end date of the project in months)	Amount of financial support (in €)
Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer (HYPMED)	EU Horizon 2020	1/2016-12/2023	106,625
Pathology Network for Sarcomas (PATHSARK)	Förderung Krebsforschung NRW e.V.	2/2016-12/2024	100,000
Genomic profiling of sarcomas – GISAR-MORNING 1.0	IKF Frankfurt	09/2020-12/2024	41,500